Additionally, detection of mesenchymal CTCs (with expression of VIM) correlated with poor patients outcome both in early [49–51] and metastatic BC (CTCs negative for epithelial cytokeratins, but expressing VIM or fibronectin) [52]. The gene discussed is VIM; the disease is breast cancer.